| __timestamp | CymaBay Therapeutics, Inc. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 2917513 |
| Thursday, January 1, 2015 | 8871000 | 7878291 |
| Friday, January 1, 2016 | 9645000 | 8366794 |
| Sunday, January 1, 2017 | 12387000 | 6610381 |
| Monday, January 1, 2018 | 14381000 | 6556000 |
| Tuesday, January 1, 2019 | 19238000 | 6930000 |
| Wednesday, January 1, 2020 | 17425000 | 8758000 |
| Friday, January 1, 2021 | 23040000 | 10806000 |
| Saturday, January 1, 2022 | 25116000 | 9844000 |
| Sunday, January 1, 2023 | 51953000 | 13481000 |
Unleashing the power of data
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, CymaBay Therapeutics, Inc. and Soleno Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, CymaBay's SG&A expenses surged by over 500%, peaking in 2023. This reflects their aggressive expansion strategy. In contrast, Soleno maintained a more conservative approach, with expenses increasing by approximately 360% over the same period. Notably, CymaBay's expenses in 2023 were nearly four times higher than Soleno's, indicating a significant divergence in their operational strategies. This data highlights the strategic choices companies make in balancing growth and cost management, offering valuable insights for investors and industry analysts alike.
Breaking Down SG&A Expenses: Novo Nordisk A/S vs Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: AbbVie Inc. vs Soleno Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Merck & Co., Inc. and CymaBay Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Bristol-Myers Squibb Company and CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Insmed Incorporated vs CymaBay Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and Soleno Therapeutics, Inc.
Comparing SG&A Expenses: Blueprint Medicines Corporation vs Soleno Therapeutics, Inc. Trends and Insights
Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Bausch Health Companies Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared